Skip to main content

16-08-2017 | Oncology | News | Article

News in brief

Low vitamin D linked to increased relapse risk after HSCT for myeloid malignancies

medwireNews: Among patients with myeloid malignancies, vitamin D deficiency prior to undergoing allogeneic hematopoietic stem cell transplantation (HSCT) could affect disease control, find German researchers.

After adjusting for confounders such as disease stage and conditioning intensity, they found that, among patients with myeloid or lymphoid malignancies, vitamin D deficiency was associated with worse overall survival (OS; hazard ratio [HR]=1.78). The association appeared to be driven primarily by the increased risk for relapse in patients with myeloid disease (HR=2.55).

And vitamin D deficiency was common, with 25-hydroxyvitamin D3 levels below 20 ng/mL found in 80% of the 492 patients included in the study. It was also present in 87% of an independent cohort of 398 patients with myeloid malignancies and had a similar impact on relapse risk, although there was no effect on OS.

“[Vitamin D] status represents an easily modifiable patient risk factor,” say Thomas Luft, from the University Hospital Heidelberg, and co-researchers in the Journal of Clinical Oncology, adding that their findings “provide a rationale for the design of interventional studies.”

By Shreeya Nanda

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group

See the research in context now

with trial summaries, expert opinion and congress coverage